Esperion Therapeutics Inc (ESPR) is down 1.28% Friday In Premarket Trading

Esperion Therapeutics Inc (ESPR) has fallen Friday morning, with the stock declining -1.28% in pre-market trading to 1.54. ESPR's short-term technical score of 26 indicates that the stock has traded less bullishly over the last month than 74% of stocks on the market. In the Drug Manufacturers - Specialty & Generic industry, which ranks 132 out of 146 industries, ESPR ranks higher than 37% of stocks. Esperion Therapeutics Inc has fallen 72.09% over the past month, closing at $6.20 on February 24. During this period of time, the stock fell as low as $1.46 and as high as $6.75. ESPR has an average analyst recommendation of Buy. The company has an average price target of $9.55.

ESPR has an Overall Score of 41. Find out what this means to you and get the rest of the rankings on ESPR!

See Full ESPR Report

Esperion Therapeutics Inc has a Long-Term Technical rank of 1. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 99% of the market scoring higher. In the Drug Manufacturers - Specialty & Generic industry which is number 135 by this metric, ESPR ranks better than 135% of stocks.

Important Dates for Investors in ESPR:

-Esperion Therapeutics Inc is set to release earnings on 5/2/2023. Over the last 12 months, the company has reported EPS of $-3.53. -We do not have a set dividend date for Esperion Therapeutics Inc at this time. Click Here To Get The Full Report on Esperion Therapeutics Inc (ESPR)